FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023394373> ?p ?o ?g. }

• W2023394373 endingPage "2027" @default.
• W2023394373 startingPage "2022" @default.
• W2023394373 abstract "SummaryBackground: Antiplatelet drugs constitute the therapy of choice for acute coronary syndromes, but bleeding can be a side‐effect requiring treatment. Restoration of normal platelet activity is also mandatory before urgent surgery. This study investigated: (a) whether a regimen of aspirin or clopidogrel plus aspirin significantly inhibited platelet thrombin generation (TG); and (b) the reversal of this inhibition by recombinant activated factor VII (rFVIIa). Methods and results: TG was evaluated by the lag time, time to peak, peak of TG, and area under the curve after 35 min of assay (AUC0 → 35 min). These measures were examined by the calibrated automated thrombography method in 22 healthy volunteers, 22 volunteers after a 100 mg day−1 aspirin intake (200 mg first day) for 5–7 days, and 22 healthy volunteers after aspirin 100 mg day−1 (200 mg first day) plus clopidogrel 75 mg day−1 (300 mg first day) for 4–7 days. The TG parameters were measured under basal conditions and after platelet stimulation by sodium arachidonate (AA), adenosine 5′‐diphosphate (ADP), collagen and rFVIIa in normal non‐aspirinated as well as in vivo aspirinated platelet‐rich plasma (PRP) or aspirin plus clopidogrel PRP. Lag time was shorter (P < 0.05), and peak of TG and AUC0 → 35 min were significantly greater (P < 0.01 for both), in PRP activated with ADP, collagen, AA or FVIIa than in non‐activated PRP from normal subjects. Both non‐activated PRP and activated PRP prepared from platelets obtained from volunteers after aspirin intake showed significant prolongation of the time parameters but there was less effect on peak of TG and AUC0 → 35 min. For most parameters, aspirin plus clopidogrel administration showed to be more effective compared with the effect obtained by aspirin alone. When rFVIIa was added to ASA‐PRP or ASA + Clop PRP, lag time (P < 0.001 for all) and time to peak (P < 0.001–0.017) were significantly shortened, indicating that rFVIIa reverses the inhibitory effect of these anti‐aggregating agents. Conclusion: Platelets activated by AA, ADP, collagen or FVIIa triggered TG. This effect was inhibited by aspirin plus clopidogrel, suggesting an additional benefit of this drug combination for preventing thrombosis. rFVIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel, and could be useful for bleeding complications or when acute surgery is needed during treatment with these antiplatelet drugs. Background: Antiplatelet drugs constitute the therapy of choice for acute coronary syndromes, but bleeding can be a side‐effect requiring treatment. Restoration of normal platelet activity is also mandatory before urgent surgery. This study investigated: (a) whether a regimen of aspirin or clopidogrel plus aspirin significantly inhibited platelet thrombin generation (TG); and (b) the reversal of this inhibition by recombinant activated factor VII (rFVIIa). Methods and results: TG was evaluated by the lag time, time to peak, peak of TG, and area under the curve after 35 min of assay (AUC0 → 35 min). These measures were examined by the calibrated automated thrombography method in 22 healthy volunteers, 22 volunteers after a 100 mg day−1 aspirin intake (200 mg first day) for 5–7 days, and 22 healthy volunteers after aspirin 100 mg day−1 (200 mg first day) plus clopidogrel 75 mg day−1 (300 mg first day) for 4–7 days. The TG parameters were measured under basal conditions and after platelet stimulation by sodium arachidonate (AA), adenosine 5′‐diphosphate (ADP), collagen and rFVIIa in normal non‐aspirinated as well as in vivo aspirinated platelet‐rich plasma (PRP) or aspirin plus clopidogrel PRP. Lag time was shorter (P < 0.05), and peak of TG and AUC0 → 35 min were significantly greater (P < 0.01 for both), in PRP activated with ADP, collagen, AA or FVIIa than in non‐activated PRP from normal subjects. Both non‐activated PRP and activated PRP prepared from platelets obtained from volunteers after aspirin intake showed significant prolongation of the time parameters but there was less effect on peak of TG and AUC0 → 35 min. For most parameters, aspirin plus clopidogrel administration showed to be more effective compared with the effect obtained by aspirin alone. When rFVIIa was added to ASA‐PRP or ASA + Clop PRP, lag time (P < 0.001 for all) and time to peak (P < 0.001–0.017) were significantly shortened, indicating that rFVIIa reverses the inhibitory effect of these anti‐aggregating agents. Conclusion: Platelets activated by AA, ADP, collagen or FVIIa triggered TG. This effect was inhibited by aspirin plus clopidogrel, suggesting an additional benefit of this drug combination for preventing thrombosis. rFVIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel, and could be useful for bleeding complications or when acute surgery is needed during treatment with these antiplatelet drugs." @default.
• W2023394373 created "2016-06-24" @default.
• W2023394373 creator A5015645014 @default.
• W2023394373 creator A5028459053 @default.
• W2023394373 creator A5050878005 @default.
• W2023394373 creator A5059785414 @default.
• W2023394373 date "2006-09-01" @default.
• W2023394373 modified "2023-09-30" @default.
• W2023394373 title "Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation" @default.
• W2023394373 cites W1887640772 @default.
• W2023394373 cites W1934110994 @default.
• W2023394373 cites W1980150519 @default.
• W2023394373 cites W1988665858 @default.
• W2023394373 cites W1989648529 @default.
• W2023394373 cites W2001473873 @default.
• W2023394373 cites W2022177860 @default.
• W2023394373 cites W2026770299 @default.
• W2023394373 cites W2037652834 @default.
• W2023394373 cites W2043800309 @default.
• W2023394373 cites W2053898685 @default.
• W2023394373 cites W2086977057 @default.
• W2023394373 cites W2095700135 @default.
• W2023394373 cites W2104066611 @default.
• W2023394373 cites W2122203296 @default.
• W2023394373 cites W2134387821 @default.
• W2023394373 cites W2135486988 @default.
• W2023394373 cites W2141352340 @default.
• W2023394373 cites W2150612971 @default.
• W2023394373 cites W2167402278 @default.
• W2023394373 cites W2171360908 @default.
• W2023394373 cites W2334010421 @default.
• W2023394373 cites W2009137359 @default.
• W2023394373 doi "https://doi.org/10.1111/j.1538-7836.2006.02088.x" @default.
• W2023394373 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16961610" @default.
• W2023394373 hasPublicationYear "2006" @default.
• W2023394373 type Work @default.
• W2023394373 sameAs 2023394373 @default.
• W2023394373 citedByCount "71" @default.
• W2023394373 countsByYear W20233943732012 @default.
• W2023394373 countsByYear W20233943732013 @default.
• W2023394373 countsByYear W20233943732014 @default.
• W2023394373 countsByYear W20233943732015 @default.
• W2023394373 countsByYear W20233943732016 @default.
• W2023394373 countsByYear W20233943732017 @default.
• W2023394373 countsByYear W20233943732018 @default.
• W2023394373 countsByYear W20233943732019 @default.
• W2023394373 countsByYear W20233943732020 @default.
• W2023394373 countsByYear W20233943732021 @default.
• W2023394373 countsByYear W20233943732022 @default.
• W2023394373 countsByYear W20233943732023 @default.
• W2023394373 crossrefType "journal-article" @default.
• W2023394373 hasAuthorship W2023394373A5015645014 @default.
• W2023394373 hasAuthorship W2023394373A5028459053 @default.
• W2023394373 hasAuthorship W2023394373A5050878005 @default.
• W2023394373 hasAuthorship W2023394373A5059785414 @default.
• W2023394373 hasBestOaLocation W20233943731 @default.
• W2023394373 hasConcept C126322002 @default.
• W2023394373 hasConcept C2777292125 @default.
• W2023394373 hasConcept C2777399203 @default.
• W2023394373 hasConcept C2777628954 @default.
• W2023394373 hasConcept C2777849778 @default.
• W2023394373 hasConcept C2778961111 @default.
• W2023394373 hasConcept C2780076745 @default.
• W2023394373 hasConcept C2993802102 @default.
• W2023394373 hasConcept C3018697912 @default.
• W2023394373 hasConcept C42219234 @default.
• W2023394373 hasConcept C71924100 @default.
• W2023394373 hasConcept C89560881 @default.
• W2023394373 hasConcept C98274493 @default.
• W2023394373 hasConceptScore W2023394373C126322002 @default.
• W2023394373 hasConceptScore W2023394373C2777292125 @default.
• W2023394373 hasConceptScore W2023394373C2777399203 @default.
• W2023394373 hasConceptScore W2023394373C2777628954 @default.
• W2023394373 hasConceptScore W2023394373C2777849778 @default.
• W2023394373 hasConceptScore W2023394373C2778961111 @default.
• W2023394373 hasConceptScore W2023394373C2780076745 @default.
• W2023394373 hasConceptScore W2023394373C2993802102 @default.
• W2023394373 hasConceptScore W2023394373C3018697912 @default.
• W2023394373 hasConceptScore W2023394373C42219234 @default.
• W2023394373 hasConceptScore W2023394373C71924100 @default.
• W2023394373 hasConceptScore W2023394373C89560881 @default.
• W2023394373 hasConceptScore W2023394373C98274493 @default.
• W2023394373 hasIssue "9" @default.
• W2023394373 hasLocation W20233943731 @default.
• W2023394373 hasLocation W20233943732 @default.
• W2023394373 hasOpenAccess W2023394373 @default.
• W2023394373 hasPrimaryLocation W20233943731 @default.
• W2023394373 hasRelatedWork W1887640772 @default.
• W2023394373 hasRelatedWork W1975904564 @default.
• W2023394373 hasRelatedWork W1977136153 @default.
• W2023394373 hasRelatedWork W2023394373 @default.
• W2023394373 hasRelatedWork W2037652834 @default.
• W2023394373 hasRelatedWork W2075941057 @default.
• W2023394373 hasRelatedWork W2368367966 @default.
• W2023394373 hasRelatedWork W2415139564 @default.
• W2023394373 hasRelatedWork W2762500185 @default.
• W2023394373 hasRelatedWork W2799365797 @default.
• W2023394373 hasVolume "4" @default.

• next